EXHIBIT 10.8
▇▇▇▇▇▇ DRUG CO., INC.
AMENDMENT TO
DEBENTURE AND WARRANT PURCHASE AGREEMENT
DATED AS OF DECEMBER 20th, 2002
This Amendment to the Debenture and Warrant Purchase Agreement is made
as of this 20th day of December, 2002, by and among ▇▇▇▇▇▇ Drug Co., Inc., a New
York corporation (the "Company"), and each of the Purchasers set forth on the
signature page hereto (the "Purchasers").
R E C I T A L S :
WHEREAS, pursuant to that certain Debenture and Warrant Purchase
Agreement dated as of March 10, 1998 (the "Purchase Agreement") executed by the
Company in favor of the Purchasers, the Company issued its 5% Convertible Senior
Secured Debentures due March 15, 2003 (the "Existing Debentures"); and
WHEREAS, pursuant to a certain Debenture Purchase Agreement dated on or
about December 20, 2002 (the "2002 Purchase Agreement"), proposed to be executed
by the Company in favor of Care Capital LLC, Essex Woodlands Health Ventures and
the other purchasers listed on the signature page thereto, the Company proposes
to issue its 5% Convertible Senior Secured Debentures due March 31, 2006 (the
"New Debentures");
WHEREAS, as a condition to the investment in the New Debentures to be
made by the Purchasers listed in the 2002 Purchase Agreement (the "New
Holders"), the New Holders have required that the Purchase Agreement be amended
to (i) extend the maturity date of the Existing Debentures from March 15, 2003
to ▇▇▇▇▇ ▇▇, ▇▇▇▇, (▇▇) provide that the holders of the Existing Debentures have
veto rights for certain material Company transactions, (iii) provide that the
right of first refusal provided to the holders of the Existing Debentures be
exercisable on a pro rata basis with the New Holders under the 2002 Purchase
Agreement; and (iv) reduce the number of representatives designated by the
holders of the Existing Debentures from three (3) to two (2) commencing with the
second Annual Meeting of Shareholders following the date of this Amendment.
WHEREAS, as an inducement for the New Holders to make the investment
pursuant to the 2002 Purchase Agreement, the Company and the Purchasers desire
to amend the Purchase Agreement as hereinafter provided;
NOW, THEREFORE, in consideration of the foregoing recitals and the
covenants herein contained, the parties hereto agree as follows:
1. Capitalized terms used herein and not otherwise defined shall
have the meanings provided in the Purchase Agreement.
2. Section 1.1 of the Purchase Agreement is hereby amended to
delete Subsection (a) of such Section and replace same with the following:
"(a) its 5% Convertible Senior Secured Debentures due March
31, 2006 in the aggregate principal amount of $20,800,000 (the
"Debentures"),"
3. The Purchase Agreement is hereby amended to provide that the
maturity date of the Debentures shall be March 31, 2006 and that any reference
to a maturity date of March 15, 2003 shall be deemed changed to March 31, 2006.
4. The definition of Debentures as contained in Section 1.1 of
the Purchase Agreement is hereby revised to include all 5% Convertible Senior
Secured Debentures having an original maturity date of March 15, 2003 issued
pursuant to the Purchase Agreement, including, without limitation, all 5%
Convertible Senior Secured Debentures issued by the Company to the Purchasers in
satisfaction of interest payments due and payable thereunder. Exhibit A-1 to
this Amendment to the Debenture and Warrant Purchase Agreement sets forth all
Debentures and Warrants issued to the Purchasers pursuant to the Purchase
Agreement through the date hereof.
5. Each Purchaser agrees to surrender to the Company each
Debenture instrument issued to such Purchaser as described in Exhibit A-1 to
this Amendment to the Debenture and Warrant Purchase Agreement against the
issuance by the Company of an Amended and Restated 5% Convertible Senior Secured
Debenture of like principal amount due March 31, 2006 in substantially the form
attached as Exhibit B to this Amendment to Debenture and Warrant Purchase
Agreement.
6. Section 9.8 of the Purchase Agreement is hereby amended to
delete subsection (a) of such Section and replace same with the following:
"(a) The Company agrees to hold meetings of its Board
of Directors at least four (4) times a year, at no more than
three-month intervals. So long as the Purchasers own any
Securities, at each annual meeting of the Company's
Stockholders, the Purchasers shall have the right to nominate
three (3) designees to be members of the Board of Directors;
provided, however, that commencing with the Company's 2004
Annual Meeting of Shareholders, the Purchasers shall have the
right to nominate two (2) designees to be members of the Board
of Directors."
7. A new Section 9.18 is hereby added to the Purchase Agreement
as follows:
"9.18 Debentureholders Agreement. Each of the Company and the
holders of the Debentures has concurrently executed the form
of Debentureholders Agreement attached as Exhibit N hereto."
8. Section 12.1(c) of the Purchase Agreement is hereby deleted in
its entirety and the following inserted in lieu thereof:
"If the Company shall default in the performance of
any other material agreement or covenant contained in this
Agreement or in any other agreement executed in connection
with this Agreement, including that certain Registration
Rights Agreement dated December 20, 2002 among the Company,
the Purchasers and the other parties thereto, and such default
shall not have been remedied to the satisfaction of the Holder
or Holders of at least a majority in aggregate principal
amount of the Debentures then outstanding, within forty-five
(45) days after a Default Notice shall have been given to the
Company (the Company to give forwith to all other Holders of
Debentures at the time outstanding written notice of the
receipt of such Default Notice, specifying the default
referred to therein);"
9. Article XVI of the Purchase Agreement is hereby deleted in its
entirety and the following inserted in its place:
2
ARTICLE 16
RIGHT OF FIRST REFUSAL: ADDITIONAL INVESTMENT
16.1 Right of First Refusal. Each Holder of the
Debentures, Holder of Shares (provided any Debentures remain outstanding and the
Shares received upon conversion have not been sold, transferred or otherwise
disposed of) (the "Common Holder"), holders of the 2002 Debentures (the "2002
Debentureholders") and holders of shares of Common Stock issued upon the
conversion of the 2002 Debentures (provided any 2002 Debentures remain
outstanding and the shares of Common Stock received upon conversion have not
been sold, transferred or otherwise disposed of) (the "New Common Holders")
shall be entitled to the following right of first refusal:
(a) Except in the case of Excluded Securities (as
hereinafter defined), the Company shall not issue, sell or exchange, agree to
issue, sell or exchange, or reserve or set aside for issuance, sale or exchange
(i) any shares of Common Stock, (ii) any other equity security of the Company,
(iii) any debt security of the Company which by its terms is convertible into or
exchangeable for, with or without consideration, any equity security of the
Company, (iv) any security of the Company that is a combination of debt and
equity or (v) any option, warrant or other right to subscribe for, purchase or
otherwise acquire any equity security or any such debt security of the Company
(collectively, the "Equity Securities") unless in each case, the Company shall
have first offered to sell to the holders of Debentures, the Common Holders, the
2002 Debentureholders and the New Common Holders, the Equity Securities, at a
price and on such other terms as shall have been specified by the Company in
writing delivered to each of the Holders of Debentures, the Common Holders, the
2002 Debentureholders and the New Common Holders (the "Offer"), which Offer by
its terms shall remain open and irrevocable for a period of thirty (30) days
from the date it is delivered by the Company to the Holders of Debentures, the
Common Holders, the 2002 Debentureholders and the New Common Holders; provided,
however, that such issuance, sale or exchange of equity securities shall result
in gross proceeds to the Company (whether at the time of issuance or upon
conversion, exercise, or exchange thereof) of an amount in excess of $200,000
(the "Minimum Offering Threshold"). For purposes of computing the Minimum
Offering Threshold, any offering, issuance, sale or exchange of Equity
Securities during any rolling 12 month period shall be aggregated.
(b) Each of the Holders of Debentures, the Common
Holders, the 2002 Debentureholders and the New Common Holders shall have the
right to purchase its pro rata share of the Equity Securities. The "pro rata
share" of each Holder of Debentures, Common Holder, 2002 Debentureholders and
the New Common Holders shall be that amount of the Equity Securities multiplied
by a fraction, the numerator of which is the sum of (i) the Shares underlying
the Debenture held by such person if such person is the holder of a Debenture,
(ii) the number of Shares of Common Stock issued to such Common Holder upon
conversion of a Debenture if such person is a Common Holder, (iii) the number of
shares of Common Stock underlying the 2002 Debentures held by such person if
such person is a 2002 Debentureholder and (iv) the number of shares of Common
Stock issued to a 2002 Debentureholder upon conversion of a 2002 Debenture if
such person is an New Common Holder, and the denominator of which is the sum of
(x) the total number of shares of Common Stock underlying the Debentures issued
pursuant to this Agreement and (y) the total number of shares of Common Stock
underlying the 2002 Debentures.
(c) Notice of the intention of each Holder of a
Debenture, Common Holder, 2002 Debentureholder or New Common Holder to accept,
in whole or in part, an Offer shall be evidenced by a writing signed by such
person, as the case may be and delivered to the Company prior to the end of the
30-day period commencing with the date of such Offer or, if later within ten
(10) days after the delivery of giving of any written notice of a material
change in such Offer, setting forth such portion (specifying number of shares,
principal amount or the like) of the Equity Securities as such person elects to
purchase (the "Notice of Acceptance").
(d) In the event that all Holders of Debentures, Common
Holders, 2002 Debentureholders and New Common Holders do not elect to purchase
all of the Equity Securities, the persons
3
which have provided notice of their intention to exercise the refusal rights as
provided in subparagraph (c) above shall have the right to purchase, on a pro
rata basis, any unsubscribed portion of the Equity Securities during a period of
ten (10) days following the 30-day period provided in subparagraph (c) above.
Following such additional 10-day period, in the event the Holders of the
Debentures, the Common Holders, 2002 Debentureholders and the New Common Holders
have not elected to purchase all of the Equity Securities, the Company shall
have 90 days from the expiration of the foregoing 40-day period to sell all or
any part of such Equity Securities as to which a Notice of Acceptance has not
been given by any of such persons (the "Refused Securities") to any other person
or persons, but only upon terms and conditions in all material respects,
including without limitation, unit price and interest rates, which are no more
favorable, in the aggregate, to such other person or persons or less favorable
to the Company than those set forth in the Offer. Upon the closing of the sale
to such other person or persons of all of the Refused Securities, which shall
include payment of the purchase price to the Company in accordance with the
terms of the Offer, if the Holders of Debentures, the Common Holders, the 2002
Debentureholders and the New Common Holders have timely submitted a Notice of
Acceptance, it and/or they shall purchase from the Company, and the Company
shall sell to the Holders of Debentures, the Common Holders, 2002
Debentureholders and the New Common Holders, as the case may be, the Equity
Securities in respect of which a Notice of Acceptance was delivered to the
Company, at the terms specified it the Offer. The purchase by the Holders of
Debentures, Common Holders, the 2002 Debentureholders and the New Common Holders
of any Equity Securities is subject in all cases to the preparation, execution
and delivery by the Company and such persons of a purchase agreement and other
customary documentation relating to such Equity Securities as is satisfactory in
form and substance to such persons and each of their respective counsel.
(e) In each case, any Equity Securities not purchased by
the Holders of Debentures, the Common Holders, the 2002 Debentureholders and the
New Common Holders or by a person or persons in accordance with Section 16.1(d)
hereof may not be sold or otherwise disposed of until they are again offered to
such persons under the procedures specified in Section 16.1(a), (b), (c) and (d)
hereof.
(f) The rights of the Holders of Debentures, the Common
Holders, 2002 Debentureholders and the New Common Holders under this Section
16.1 shall not apply to the following securities (the "Excluded Securities"):
(i) Common Stock or options to purchase such
Common Stock, issued to officers, employees
or directors of, or consultants to, the
Company, pursuant to any agreement, plan or
arrangement approved by the Board of
Directors of the Company;
(ii) Common Stock issued as a stock dividend or
upon any stock split or other subdivision or
combination of shares of Common Stock;
(iii) Common Stock issued upon conversion of the
Debentures or the 1999 Debentures, or
exercise of the Warrants or the warrants
issued in connection with the 1999
Debentures, or Common Stock issued upon
conversion of the 2002 Debentures or
exercise of the warrants issued pursuant to
the 2002 Purchase Agreement;
(iv) Common Stock or debentures issued in
satisfaction of interest payments on the
Debentures, the 1999 Debentures and the 2002
Debentures, including the issuance of Common
Stock or Debentures issued in satisfaction
of interest payments on Debenture
instruments issued by the Company in
satisfaction of the interest payments on the
Debentures, the 1999 Debenture and the 2002
Debentures; or
(v) any securities issued for consideration
other than cash pursuant to a merger,
consolidation, acquisition, strategic
alliance or similar business
4
combination approved by the Board of
Directors and/or at the Company's Annual
Meeting of Shareholders.
(g) Notwithstanding anything to the contrary contained
herein, a Holder of a Debenture, a Common Holder (other than an initial
Purchaser), a 2002 Debentureholders or a New Common Holder (other than an
initial purchaser of a 2002 Debenture) shall not be considered as such for
purposes of this Section 16.1 only, unless such person then holds Debentures or
2002 Debentures with an outstanding principal amount of at least $200,000 or
shares issued upon conversion of at least $200,000 in principal of Debentures or
2002 Debentures or a combination of Debentures or 2002 Debentures and shares of
Common Stock received upon conversion of the Debentures and 2002 Debentures such
that the outstanding principal of the Debentures or 2002 Debentures held by such
person plus the amount of principal of Debentures or 2002 Debentures converted
into shares held by such person equals or exceeds $200,000."
10. Subparagraph (a) of Article XIII is hereby amended to add the
following at the end of such Subparagraph:
"Notwithstanding the foregoing or anything to the contrary
contained in this Article XIII, no amendment to Section 9.18
shall be valid unless the same shall be in writing and signed
by the Company and the holders of at least 66 2/3% in the
aggregate principal amount of the Debenture (including for
purposes such calculation the principal amount of those
Debentures that at such time have been converted into shares).
11. Except as amended above, the terms of the Purchase Agreement
shall remain in full force and effect.
12. This Amendment to Debenture and Warrant Purchase Agreement and
the rights of the parties hereunder shall be governed in all respects by laws in
the State of New York wherein the terms of this Amendment were negotiated.
13. This Amendment to Debenture and Warrant Purchase Agreement may
be executed in any number of counterparts, each of which shall be original, but
all of which together shall constitute one instrument.
[SIGNATURE PAGES TO FOLLOW]
5
IN WITNESS WHEREOF, the Company and the Purchasers have caused this
Amendment to be duly executed all on the day and year first above written.
▇▇▇▇▇▇ DRUG CO., INC.
By:__________________________________
Name: ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇
Title: Chief Executive Officer
PURCHASERS
▇▇▇▇▇ PARTNERS III, L.P. GALEN PARTNERS INTERNATIONAL, III, L.P.
By: Claudius, L.L.C., General Partner By: Claudius, L.L.C., General Partner
▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇ ▇▇. ▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇ ▇▇▇▇▇
▇▇▇ ▇▇▇▇, ▇▇▇ ▇▇▇▇ ▇▇▇▇▇ ▇▇▇ ▇▇▇▇, ▇▇▇ ▇▇▇▇ ▇▇▇▇▇
_____________________________________ _______________________________________
By: ▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇ By: ▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇
Its: General Partner Its: General Partner
▇▇▇▇▇ EMPLOYEE FUND III, L.P. ▇▇▇▇ ▇▇▇▇▇
By: Wesson Enterprises, Inc. ▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇
610 Fifth Avenue, 5th Floor Newport, Rhode Island 02840
▇▇▇ ▇▇▇▇, ▇▇▇ ▇▇▇▇ ▇▇▇▇▇
_____________________________________ _______________________________________
By: ▇▇▇▇▇ ▇. ▇▇▇▇▇▇
Its: General Partner
▇▇▇▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇
▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇ ▇/▇ ▇▇▇▇▇▇ ▇▇▇▇
▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇ ▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇
▇▇▇ ▇▇▇▇, ▇▇▇ ▇▇▇▇ ▇▇▇▇▇
_____________________________________ _______________________________________
▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇▇▇
▇▇▇▇ ▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇ ▇▇▇▇ ▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇
▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇
_____________________________________ _______________________________________
6
▇▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇
c/o D.R. International ▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇
▇▇▇▇ ▇▇. ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇ ▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇
_____________________________________ _______________________________________
▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇ ▇. ▇▇▇▇▇ & CO., INC., TTEE
c/▇ ▇▇▇▇▇▇ Drug Co., Inc. FBO ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ ▇▇▇
▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇ ▇▇. c/▇ ▇▇▇▇▇▇ Drug Co., Inc.
▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ #▇ ▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇ ▇▇.
Rockford, Ill. ▇▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ #▇
▇▇▇▇▇▇▇▇, ▇▇▇. ▇▇▇▇▇
_____________________________________ _______________________________________
By: ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇
Its: Trustee
▇▇▇▇▇▇ ▇▇▇▇▇▇▇ TRUST ▇▇▇▇▇ ▇▇▇▇▇▇▇
c/▇ ▇▇▇▇▇▇ Drug Co., Inc. c/▇ ▇▇▇▇▇▇ Drug Co., Inc.
▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇ ▇▇. ▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇ ▇▇.
Crimson Building #2 Crimson Building #2
Rockford, Ill. 61107 ▇▇▇▇▇▇▇▇, ▇▇▇. ▇▇▇▇▇
_____________________________________ _______________________________________
By: ▇▇▇▇▇▇ ▇▇▇▇▇▇▇
Its: Trustee
▇▇▇▇▇▇ ▇. ▇▇▇▇ ▇▇▇▇▇▇ ▇. ▇▇▇▇
▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇ ▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇▇, ▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇
_____________________________________ _______________________________________
▇▇▇▇▇▇ ▇. ▇▇▇▇ AS CUSTODIAN ▇▇▇▇▇▇ ▇. ▇▇▇▇ AS CUSTODIAN
FOR ▇▇▇▇▇▇ ▇. ▇▇▇▇ FOR ▇▇▇▇▇▇ ▇. ▇▇▇▇
▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇ ▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇▇, ▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇
_____________________________________ _______________________________________
By: Varshah ▇. ▇▇▇▇ By: Varshah ▇. ▇▇▇▇
Its: Custodian Its: Custodian
▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇▇▇
▇/▇ ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇/▇ ▇▇▇▇▇ ▇▇▇▇▇▇▇▇
▇
▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇ ▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇
▇▇▇▇▇▇▇▇▇▇▇, ▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇, ▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇
_____________________________________ _______________________________________
▇▇▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇ ACCOUNT ▇▇▇▇▇▇▇ ▇▇▇▇▇▇
FBO ▇▇▇▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇, ▇▇▇. ▇▇▇▇▇
▇▇▇▇▇▇▇▇ ▇▇▇▇, ▇▇▇. ▇▇▇▇▇
_____________________________________ _______________________________________
By:__________________________________
Its: Trustee
▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇
C/▇ ▇▇▇▇▇▇ Drug Co., Inc.
▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇ ▇▇.
▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ #▇
▇▇▇▇▇▇▇▇, ▇▇▇. ▇▇▇▇▇
_____________________________________
8
▇▇▇▇▇▇ ▇. ▇▇▇▇▇ & CO., INC., TTEE ▇▇▇▇▇▇ ▇. ▇▇▇▇▇ & CO., INC., TTEE
FBO ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇ FBO ▇▇▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇
c/▇ ▇▇▇▇▇▇ Drug Co., Inc. c/▇ ▇▇▇▇▇▇ Drug Co., Inc.
▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇ ▇▇. ▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇ ▇▇.
Crimson Building #2 Crimson Building #2
Rockford, Illinois 61107 ▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
_____________________________________ _______________________________________
By: ▇▇▇▇▇▇ ▇. ▇▇▇▇▇ By: ▇▇▇▇▇▇ ▇. ▇▇▇▇▇
Its: Trustee Its: Trustee
▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇ TRUST
c/▇ ▇▇▇▇▇▇ Drug Co., Inc.
▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇ ▇▇.
▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ #▇
▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
_____________________________________
By: ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇
Its: Trustee
9
EXHIBIT A-1
LIST OF DEBENTURE HOLDERS
10
EXHIBIT B
FORM OF AMENDED AND RESTATED
5% CONVERTIBLE SENIOR SECURED DEBENTURE
11
EXHIBIT N
DEBENTUREHOLDER AGREEMENT
12